Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "Elutia Inc.", but the filing text identifies the registrant as Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2022
Reporting Period: Quarter and year ended December 31, 2021
Business Overview: The Company is an emerging growth company incorporated in Delaware, trading on the Nasdaq Global Market under the symbol "AZYO". This filing announces the issuance of a press release regarding financial results for the period ended December 31, 2021.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: The filing text does not provide a clear value for any specific financial metric; these are contained in the referenced Exhibit 99.1.
Material Changes
No material changes or comparative financial data are detailed in this specific document. The filing serves solely to notify the market of the release of the financial results for the quarter and year ended December 31, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the full text of the press release is furnished as Exhibit 99.1 and incorporated by reference. No specific commentary, guidance, or outlook is present in the cover document.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in this Current Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that Section, except as expressly set forth by specific reference in other filings.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated March 3, 2022), as they are not listed in this summary document.
- Confirm the company name is Aziyo Biologics, Inc. (Ticker: AZYO), as the request metadata incorrectly identified it as "Elutia Inc."
- Review the full press release for any forward-looking statements or updated clinical trial milestones not captured in this 8-K cover page.
- Check the Company's status as an Emerging Growth Company for potential differences in financial reporting standards.